Drug updated on 4/16/2024
| Dosage Form | Injection (intravitreal; 20 mg/mL in a single-dose vial) |
| Drug Class | Complement inhibitors |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
Summary
- Avacincaptad pegol (Izervay) is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). It is beneficial in reducing GA lesion growth, especially in participants with extrafoveal or juxtafoveal GA, but it does not significantly improve best-corrected visual acuity.
- Two studies provided information about Izervay's safety and effectiveness compared to other treatments like Lampalizumab and Pegcetacoplan.
- Izervay demonstrated higher reduction rates, between 25.6% to 30.5%, in GA lesion growth compared to Lampalizumab and Pegcetacoplan, which did not significantly impact this parameter.
- The safety profile of Izervay did not report any cases of endophthalmitis, suggesting a potentially lower risk compared to other intravitreal treatments like Lampalizumab and Pegcetacoplan, which presented small but notable risks.
- All three treatments, including Izervay, showed an increased risk for the development of macular neovascularization, indicating a concern for worsening AMD status; however, the evidence supporting this was of low certainty for all treatments.
- There was little difference in systemic adverse events among these treatments compared with sham procedures, but ocular treatment-emergent adverse effects occurred more frequently, especially due to new onset neovascular AMD resulting from complement inhibition.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Izervay (avacincaptad pegol) Prescribing Information. | 2023 | IVERIC Bio, Inc., Cranbury, NJ |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Complement inhibitors for age-related macular degeneration. | 2023 | The Cochrane Database of Systematic Reviews |
| The effect of complement C3 or C5 inhibition on geographic atrophy secondary to age-related macular degeneration: a living systematic review and meta-analysis. | 2023 | Survey of Ophthalmology |